Clinical experience with monoclonal antibodies to epidermal growth factor receptor
- 1 April 2005
- journal article
- review article
- Published by Springer Nature in Current Oncology Reports
- Vol. 7 (2) , 96-103
- https://doi.org/10.1007/s11912-005-0034-9
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell CancerJournal of Clinical Oncology, 2004
- Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR)Cancer Research, 2004
- Targeting the Epidermal Growth Factor Receptor: An Important Incremental Step in the Battle Against Colorectal CancerJournal of Clinical Oncology, 2004
- Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004
- Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibodyInternational Journal of Radiation Oncology*Biology*Physics, 2004
- Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004
- The epidermal growth factor receptor–tyrosine kinase: A promising therapeutic target in solid tumorsSeminars in Oncology, 2003
- Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasiaSeminars in Oncology, 2002
- Influence of Unrecognized Molecular Heterogeneity on Randomized Clinical TrialsJournal of Clinical Oncology, 2002
- The EGFR as a target for anticancer therapy—focus on cetuximabEuropean Journal Of Cancer, 2001